| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 174,858 | 192,037 | ||
| Short-term investments | 177,244 | 115,745 | ||
| Accounts receivable, net | 51,742 | 31,910 | ||
| Inventory | 41,396 | 48,181 | ||
| Prepaid expenses and other current assets | 30,290 | 32,438 | ||
| Total current assets | 475,530 | 420,311 | ||
| Property and equipment, net | 1,655 | 1,076 | ||
| Operating lease right-of-use assets | 10,073 | 10,304 | ||
| Other long-term assets | 8,288 | 8,195 | ||
| Intangible asset, net | 15,500 | 15,750 | ||
| Deferred tax assets | 201,287 | 205,514 | ||
| Total assets | 712,333 | 661,150 | ||
| Accounts payable | 6,150 | 8,956 | ||
| Accrued collaboration expenses | 63,282 | 52,389 | ||
| Accrued expenses | 30,941 | 35,959 | ||
| Operating lease liabilities | 2,696 | 2,522 | ||
| Other current liabilities | 20,523 | 18,001 | ||
| Total current liabilities | 123,592 | 117,827 | ||
| Non-current deferred revenue | 31,811 | 31,811 | ||
| Non-current operating lease liabilities | 7,022 | 7,243 | ||
| Other long-term liabilities | 14,525 | 9,262 | ||
| Total liabilities | 176,950 | 166,143 | ||
| Ordinary shares value-Common Class A | 12 | 12 | ||
| Ordinary shares value-Common Class B | 1 | 1 | ||
| Ordinary shares value-Common Class A1 | 4 | 4 | ||
| Ordinary shares value-Common Class B1 | 4 | 4 | ||
| Additional paid-in capital | 1,011,854 | 989,811 | ||
| Accumulated other comprehensive loss | -155 | -53 | ||
| Accumulated deficit | -476,337 | -494,772 | ||
| Total shareholders' equity | 535,383 | 495,007 | ||
| Total liabilities and shareholders' equity | 712,333 | 661,150 | ||
Kiniksa Pharmaceuticals International, plc (KNSA)
Kiniksa Pharmaceuticals International, plc (KNSA)